Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Sponsor: NMD Pharma A/S
Summary
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Official title: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2024-05-16
Completion Date
2026-05
Last Updated
2026-03-10
Healthy Volunteers
No
Conditions
Interventions
NMD670
Tablets taken twice a day for 21 days
Placebo
Tablets taken twice a day for 21 days
Locations (39)
Profound Research LLC
Carlsbad, California, United States
University of California Irvine Medical Center
Irvine, California, United States
University of Colorado Neuromuscular Division
Aurora, Colorado, United States
SFM Clinical Research, LLC
Boca Raton, Florida, United States
Neuromuscular Research Division | University of South Florida
Tampa, Florida, United States
Augusta University, Neuroscience Center
Augusta, Georgia, United States
NextGen Precision Health
Columbia, Missouri, United States
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
University of Oregon
Portland, Oregon, United States
Semmes Murphey Clinic
Memphis, Tennessee, United States
UZ Leuven
Leuven, Belgium
Aarhus University Hospital
Aarhus, Denmark
Rigshospitalet University of Copenhagen
Copenhagen, Denmark
Centre de référence des maladies neuromusculaires AOC-CHU de Bordeaux - Hôpital Pellegrin
Bordeaux, France
Centre de Référence des Maladies Neuromusculaires et de la SLA
Marseille, France
Centre Hospitalier Universitaire de Nantes - Hôtel Dieu Centre de Référence des Maladies Neuromusculaires Rares -
Nantes, France
CHU de Nice
Nice, France
Unité de Recherche Clinique NeuroSciences
Nice, France
JSC Curatio
Tbilisi, Georgia
LTD David Tatishvili Health Center
Tbilisi, Georgia
Ltd New Hospitals
Tbilisi, Georgia
ASST Papa Giovanni XXIII (Azienda Ospedaliera Papa Giovanni XXIII)
Bergamo, Italy
IRCCS Istituo delle Scienze neurologiche di Bologna, UOC Clinica neurologica Ospedale
Bologna, Italy
IRCCS Ospedale Policlinico San Martino
Genova, Italy
IRCCS Fondazione Istituto Neurologico Carlo Besta, Dipartimento di Ricerca e Sviluppo clinico
Milan, Italy
DIMER, IRCCS, Ospedale San Raffaele
Milan, Italy
Centro Sclerosi Multipla Napoli - AOU Vanvitelli
Naples, Italy
AOU Pisana
Pisa, Italy
Azienda Ospedaliera Sant'Andrea - Universita di Roma La Sapienza
Roma, Italy
Leiden Universitair Medisch Centrum (LUMC)
Leiden, Netherlands
Neurologia Śląska Centrum Medyczne
Katowice, Poland
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie sp.z o.o
Krakow, Poland
Centrum Medyczne Hope Clinic
Lublin, Poland
Galen Clinic
Lublin, Poland
Centrum Medyczne Neuro Protect
Warsaw, Poland
University Clinical Center of Serbia, Neurology Clinic
Belgrade, Serbia
University Clinical Center Nis, Neurology Clinic
Niš, Serbia
Hospìtal Universitari Vall d'Hebrón
Barcelona, Spain